Zentalis Pharmaceuticals (ZNTL) Return on Capital Employed (2020 - 2026)
Zentalis Pharmaceuticals' quarterly Return on Capital Employed came in at 61.51% in Q1 2026, down 224.0% year-on-year from 49.61% in Q1 2025, and down 9.32% quarter-over-quarter from 56.27% in Q4 2025.
Zentalis Pharmaceuticals has reported Return on Capital Employed for 7 years, with the latest figure at 61.51% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 224.0% year-over-year to 61.51%; the trailing twelve-month figure through Mar 2026 stood at 61.51% (down 224.0% YoY), and the FY2025 full-year result was 47.3%, down 367.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 61.51%, down from 56.27% in the prior quarter.
- The five-year high for Return on Capital Employed was 45.25% in Q3 2022, with the low at 61.51% in Q1 2026.
- Average Return on Capital Employed over 5 years is 53.45%, with a median of 53.04% recorded in 2022.
- Year-over-year, Return on Capital Employed soared 1992 bps in 2022 and tumbled 1239 bps in 2023.
- Tracing ZNTL's Return on Capital Employed over 5 years: stood at 47.59% in 2022, then decreased by 26 bps to 59.98% in 2023, then advanced by 18 bps to 49.31% in 2024, then fell by 14 bps to 56.27% in 2025, then decreased by 9 bps to 61.51% in 2026.
- The last three Return on Capital Employed figures came in at 61.51% (Q1 2026), 56.27% (Q4 2025), and 54.67% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | -61.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.51% |
| Dec 31, 2025 | -56.27% |
| Sep 30, 2025 | -54.67% |
| Jun 30, 2025 | -55.64% |
| Mar 31, 2025 | -59.27% |
| Dec 31, 2024 | -49.31% |
| Sep 30, 2024 | -50.27% |
| Jun 30, 2024 | -48.17% |
| Mar 31, 2024 | -51.89% |
| Dec 31, 2023 | -59.98% |
| Sep 30, 2023 | -52.02% |
| Jun 30, 2023 | -54.57% |
| Mar 31, 2023 | -51.17% |
| Dec 31, 2022 | -47.59% |
| Sep 30, 2022 | -45.25% |
| Jun 30, 2022 | -53.04% |
| Mar 31, 2022 | -57.96% |
| Dec 31, 2021 | -54.02% |
| Sep 30, 2021 | -65.16% |
| Jun 30, 2021 | -66.22% |
| Mar 31, 2021 | -48.62% |
| Dec 31, 2020 | -33.86% |
| Sep 30, 2020 | -31.01% |
| Jun 30, 2020 | -45.43% |
| Mar 31, 2020 | -77.21% |